Multiple Sclerosis Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight

Las Vegas, USA, July 06, 2022 (GLOBE NEWSWIRE) -- Multiple Sclerosis Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight 

As per DelveInsight Multiple Sclerosis pipeline involves 100+ key companies developing 100+ Multiple Sclerosis treatment therapies

DelveInsight's Multiple Sclerosis Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Multiple Sclerosis pipeline domain. 

Some of the essential takeaways from the Multiple Sclerosis pipeline report:

  • DelveInsight's Multiple Sclerosis pipeline analysis depicts a robust space with 100+ active players working to develop 100+ pipeline treatment therapies
  • Some of the key Multiple Sclerosis pipeline companies working to develop potential drug candidates to improve the Multiple Sclerosis treatment scenario include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Pipeline Therapeutics, GlaxoSmithKline, Lucid Psycheceuticals, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, Novartis,  Polpharma Biologics, Apimeds, InnoCare Pharma,  Oryzon Genomics, AbbVie,  Takeda, Medsenic,  ImCyse, H. Lundbeck A/S, Guangzhou Lupeng Pharmaceutical Company LTD, Gilead Sciences, MediciNova, Roche, FibroBiologics, 4dpharmaplc, NervGen Pharma, and several others.
  • Essential Multiple Sclerosis therapies such as Ublituximab, IMU-838, ATA188, ANK-700, IMS001, Evobrutinib, NeuroVax, CNM Au 8, GSK 3888130B, Temelimab, Belimumab, ABN101, ABX 002, Glatiramer acetate controlled release, Pear-006, GB7208, IC 100-01, Lucid MS, SAR441344, PIPE 307, ATL 1102, 11C-BMS-986196, Fenebrutinib, SAR 441344, RC18, BIIB061, Masitinib, BCD-132, HuL001, EHP-101, IR 902, PB-006, Apitox, Orelabrutinib, Vafidemstat,  Elezanumab, Ixazomib, Arscimed, IMCY-0141, Lu AG06466, Remibrutinib, Tolebrutinib,  LP-168, NurOwn, VEMLIDY, ibudilast, PIPE-307, RG-6035, MRx0002, NVG-291 and others are under development in different phases of clinical studies.
  • In March 2022,  Pipeline Therapeutics announced that it is all set to commence the Phase Ib/IIa clinical trial of its lead program, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients. The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial.
  • In June 2022 the Food and Drug Administration (FDA) extended the review period for the Biologics License Application (BLA) for ublituximab for the treatment of patients with relapsing forms of multiple sclerosis (RMS).The new Prescription Drug User Fee Act (PDUFA) target date is December 28, 2022. The FDA extended the goal date to allow time to review additional clinical information that was deemed to be a major amendment to the application.
  • In June 2022, Tiziana Life Sciences reported positive clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program at the Brigham and Women's Hospital (BWH), Boston, MA. These results confirmed the previously reported data, from the first SPMS patient after three months of treatment of the first SPMS patient. The treatment with foralumab, a fully human anti-CD3 monoclonal antibody, was well-tolerated and improved clinical and PET imaging analyses.
  • In June 2022, Pasithea Therapeutics Corp. announced its acquisition of Alpha-5 integrin, LLC ("Alpha-5"), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis ("ALS") and other neuroinflammatory disorders, such as Multiple Sclerosis ("MS").
  • In April 2021, Samsung Biologics and TG announced an expansion of a large-scale contract manufacturing deal for the supply of TG Therapeutics' ublituximab, an investigational anti-CD20 monoclonal antibody.

Request a sample and discover more about the report offerings @ Multiple Sclerosis Emerging Therapies

The Multiple Sclerosis pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Multiple Sclerosis products, inactive and dormant assets, and a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Multiple Sclerosis pipeline landscape.

Multiple Sclerosis Overview

Multiple sclerosis is a chronic disease affecting the central nervous system (the brain and spinal cord). Multiple sclerosis occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibers) in the brain and spinal cord. This attack causes inflammation, which destroys nerve cell processes and myelin – altering electrical messages in the brain. Multiple sclerosis is unpredictable and affects each patient differently – some individuals may be mildly affected, while others may lose their ability to write, speak or walk.

Understand more about the prevalent diabetic disease @ Multiple Sclerosis Pipeline Drugs Assessment 

Multiple Sclerosis Pipeline Drugs

Drug Company Phase MoA RoA
NeuroVax Immune Response BioPharma, Inc. Phase II/III Immunostimulants Intramuscular
Ublituximab TG Therapeutics Pre-Registration  T lymphocyte stimulant Intravenous
IMU-838 Immunic Phase III Dihydroorotate dehydrogenase inhibitor Oral
ATA188 Atara Biotherapeutics Phase I/II T lymphocyte replacement Intravenous
Ixazomib Takeda Phase I Proteasome inhibitor Oral
HuL001 HuniLife Biotechnology Phase I ENO1 protein inhibitor Parenteral
ATL1102 Antisense Therapeutics Phase II Integrin alpha4 inhibitor; Integrin alpha4beta1 antagonist NA
Temelimab GeNeuro SA Phase II Toll-like receptor 4 antagonist Intravenous
Arscimed Medsenic Preclinical Apoptosis stimulant NA

Learn more about the novel and emerging @ Multiple Sclerosis Pipeline Analysis

Multiple Sclerosis Therapeutics Assessment

The Multiple Sclerosis Pipeline report proffers an integral view of the Multiple Sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Multiple Sclerosis Pipeline Report 

  • Coverage: Global 
  • Therapeutic assessment by Multiple Sclerosis product type: mono, combination, mono/combination
  • Therapeutic assessment by Multiple Sclerosis clinical stages: discovery, preclinical, Phase I, Phase II, Phase III, preregistration, inactive candidates
  • Therapeutics assessment by Multiple Sclerosis route of administration: oral, parenteral, intravenous, subcutaneous, topical
  • Therapeutics assessment by Multiple Sclerosis molecule type: monoclonal antibody, peptides, polymer, small molecule, gene therapy
  • Therapeutics assessment by Multiple Sclerosis mechanism of action: agammaglobulinaemia tyrosine kinase inhibitor, Interferon beta stimulant, Integrin alpha4beta1 antagonist, Dihydroorotate dehydrogenase inhibitor, MHC class II gene modulator, CD20 antigen inhibitor, Bruton's tyrosine kinase (BTK) inhibitor, Immunostimulant, Immunomodulator, Lysine specific demethylase 1 inhibitor, Toll-like receptor 4 antagonist, RGMA protein inhibitor, Cannabinoid receptor CB2 agonist, Endothelial PAS domain-containing protein 1 inhibitor, Peroxisome proliferator-activated receptor gamma agonist, Protein phosphatase 2A stimulant, Myelin protein stimulant, Tumour necrosis factor ligand superfamily member 13 inhibitor, Immunologic cytotoxicity, T lymphocyte replacement, Proteasome inhibitor, ENO1 protein inhibitor.
  • Key Multiple Sclerosis companies: TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Pipeline Therapeutics, GlaxoSmithKline, Lucid Psycheceuticals, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, Novartis,  Polpharma Biologics, Apimeds, InnoCare Pharma,  Oryzon Genomics, AbbVie,  Takeda, Medsenic,  ImCyse, H. Lundbeck A/S, Guangzhou Lupeng Pharmaceutical Company LTD, Gilead Sciences, MediciNova, Roche, FibroBiologics, 4dpharmaplc, NervGen Pharma.
  • Key Multiple Sclerosis pipeline therapies: Ublituximab, IMU-838, ATA188, ANK-700, IMS001, Evobrutinib, NeuroVax, CNM Au 8, GSK 3888130B, Temelimab, Belimumab, ABN101, ABX 002, Glatiramer acetate controlled release, Pear-006, GB7208, IC 100-01, Lucid MS, SAR441344, PIPE 307, ATL 1102, 11C-BMS-986196, Fenebrutinib, SAR 441344, RC18, BIIB061, Masitinib, BCD-132, HuL001, EHP-101, IR 902, PB-006, Apitox, Orelabrutinib, Vafidemstat,  Elezanumab, Ixazomib, Arscimed , IMCY-0141, Lu AG06466, Remibrutinib, Tolebrutinib,  LP-168, NurOwn, VEMLIDY, ibudilast, PIPE-307, RG-6035, MRx0002, NVG-291.

Dive deep into rich insights for emerging therapies and assessment, visit @ Multiple Sclerosis Pipeline Drugs  

Table of Contents 

1 Introduction
2 Executive Summary
3 Multiple Sclerosis: Overview
4 Pipeline Therapeutics
5 Late Stage Products (Phase III)
5.1 Ublituximab: TG Therapeutics
6 Mid Stage Products (Phase II)
6.1 EHP 101: Emerald Health Pharmaceuticals
7 Early Stage Products (Phase I)
7.1 ASLAN 003: ASLAN Pharmaceuticals
8 Therapeutic Assessment
9 Inactive Products
10 Collaborations Assessment – Licensing/Partnering/Funding
11 Multiple Sclerosis – Unmet Needs
12 Multiple Sclerosis – Market Drivers and Barriers
13 Appendix
14 About DelveInsight

For further information on the Multiple Sclerosis current pipeline therapeutics, reach out @ Multiple Sclerosis Ongoing Clinical Trials 

Related Reports

Multiple Sclerosis Market

DelveInsight's ‘Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast—2032' report delivers an in-depth understanding of Multiple Sclerosis (MS), historical and forecasted epidemiology as well as the market trends, market drivers and barriers, and key Multiple Sclerosis companies involved like Immune Response BioPharma, Inc, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds Inc, Bayer HealthCare, and many more.

Relapsing-Remitting Multiple Sclerosis Pipeline

DelveInsight's, "Relapsing-Remitting Multiple Sclerosis Pipeline Insight, 2022," report provides comprehensive insights about 28+ companies and 28+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis pipeline landscapes. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Relapsing-Remitting Multiple Sclerosis companies including TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, and many more.

Chronic Hand Eczema Pipeline

DelveInsight's "Chronic Hand Eczema - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Hand Eczema pipeline landscape covering pipeline drug profiles, clinical and non-clinical stage products, treatments, key companies including LEO Pharma, Asana BioSciences, Arcutis, and many others.

Primary Progressive Multiple Sclerosis Pipeline

DelveInsight's, "Primary Progressive Multiple Sclerosis Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Primary Progressive Multiple Sclerosis pipeline landscapes. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Primary Progressive Multiple Sclerosis companies involved such as Atara Biotherapeutics, AB Science, Sanofi, MediciNova, and many others.

Persistent Epithelial Defect Market

DelveInsight's "Persistent Corneal Epithelial Defects (PEDs) - Market Insights, Epidemiology, and Market Forecast - 2032" report provides a detailed overview of the disease. Key companies include Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others are developing Persistent Epithelial Defect therapies. 

Huntington's Disease Pipeline

DelveInsight's, "Huntington's Disease Pipeline Insight, 2022," report offers rich insights into epidemiology, treatments, pipeline therapies, and key companies including Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and several others. 

Interested to know more about the breakthrough happenings? Take a look at the posts below

Other Trending Healthcare Reports 

Ischemic Stroke Market | Paget's Disease Market | Resorbable Vascular Scaffold Market | Rosai-Dorfman disease (RDD) Market | Salivary Gland Infection Market | Sandhoff Disease Market | Scedosporium Infection Market | Structural Heart Devices Market | Vascular Graft Devices Market | Vascular Stents Market | Vein Illumination Devices Market | Ventricular Assist Devices (VAD) Market | Adrenocortical Carcinoma Market | Cystinuria Market Market

About DelveInsight

DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 


Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Posted In: technical analysisHealth CareAnalyst RatingsPress Releases

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.